You are here



Andrew Morris, M.Sc., MBA

President and Chief Executive Officer

Andrew joined SQI Diagnostics as Chief Financial Officer in 2004 to grow and enhance the company's financial position and corporate strategy.

Prior to joining SQI, Andrew led the Corporate Finance Life Sciences group at Ernst & Young, advising private and public companies on a variety of business strategy and financial matters, including private equity offerings, mergers and acquisitions, and strategic alliances.

He previously gained considerable transaction experience while working in senior corporate development and finance roles in high-growth and startup companies. He also gained valuable capital markets and equity research experience at Scotia Capital, while covering companies in the healthcare and biotechnology sector.

Andrew spent eight years researching human performance enhancement at the Defence and Civil Institute of Environmental Medicine, Canada. He holds an Honours Bachelor of Science from the University of Western Ontario, a Master's of Science from the Faculty of Medicine at the University of Toronto, and a Master's of Business Administration degree from the Rotman School of Management at the University of Toronto.

Jaymie R. Sawyer, Ph.D.

Vice President, R&D

Jaymie came to SQI Diagnostics as a leader in the field of protein arrays and multiplex immunoassay development.

A molecular biologist and antibody engineer, Jaymie has expertise in both hybridoma and phage display antibody discovery. As a founding member of Motorola BioChip Systems, she was responsible for the inception and development of protein arrays on the Codelink platform, as well as developing applications for microfluidic and novel detection technologies. Jaymie later moved to BD Biosciences where she was responsible for setting up a fully automated, high-throughput screening lab for phage libraries in collaboration with Dyax Corp. As R&D Director with BD Biosciences she led reagent and assay development, plus the Cytometric Bead Array program, bringing high-value multiplexed research immunoassays to market.

With experience developing both bead-based and planar arrays, Jaymie has the know-how to develop our multiplexed assay technology and accelerate our product pipeline into the IVD market. She received her Ph.D. in genetics from the University of Wisconsin.

Russell Peloquin

Vice President, Global Commercial Operations

Russell has spent many years in commercial management with biotechnology companies, leading high-level contract negotiations in the clinical diagnostics arena and working in the field of molecular multiplexing. A portfolio of international sales and business development experience includes commercializing a product with an international diagnostic startup that was subsequently acquired.

He previously oversaw the largest geography for the diagnostic business unit of a leading multiplexing technology company where he successfully created the market for and launched several molecular diagnostic assay products and automation systems that have become multi-million dollar revenue drivers. He was a nationally known leader for the world's largest clinical reference laboratory where his responsibilities included multi-million dollar contract negotiations, new laboratory equipment evaluation, sales and logistics management, and experience in M&A.

Russell leads SQI Diagnostics' business, strategy, sales, marketing, business development, customer solutions, field/technical support, and distributor and partner relations.

Patricia Lie, CPA, CA

Vice President Finance and Administration

Patricia brings over 20 years of financial and strategic management experience and for the past five years Ms. Lie has held the position of Director of Finance and Administration at SQI. Prior to joining SQI, Ms. Lie was Professor of Business (Accounting) at Sheridan College; held various roles at Toronto Dominion Bank Financial Group following five years at PwC LLP, a Canadian public audit firm.

Ms. Lie holds a B.Comm degree from the University of Windsor. She holds a Chartered Accountant designation from the Chartered Professional Accountants Ontario and is a Certified Financial Analyst (CFA).

Aye Nyein San M.A. Sc.

Vice President Engineering

Aye brings over 10 years of experience in the medical device industry, developing prototypes to IVD products within the ISO 13485 quality system. Aye has a breath of experience in the areas of system automation, software design, usability (UI/UX) features, image processing and liquid handling systems.

Aye earned a promotion to her current role in 2017, after serving as the company’s director of platform engineering since 2013. Aye oversees a team of automation and software engineers in the design, development and operations of the SQI automation systems and fulfilling the specifications of SQI product roadmap.

Aye holds a Bachelors of Applied Science (Honours Systems Design Engineering) degree from the University of Waterloo, and a Masters of Applied Science (Mechanical and Industrial Engineering) degree from the University of Toronto, with specialization in mechatronics and microfluidics.

Peter Lea, Ph.D.


Peter invented and patented the multiplexing microarray technology at the core of SQI Diagnostics. As such, he commercialized the world's first microarray diagnostic platform incorporating automation, calibration and normalization in each test well. His breakthrough is also the first to multiplex at the antigen and antibody subclass level.

He has been instrumental in managing the company’s IP portfolio, with four patents issued (and 15 pending) to support the complexity and uniqueness of the SQI Diagnostics multiplexing microarray system.

Prior to SQI Diagnostics, Peter was Director of Biophysics, then Director of Research and Development at Spectral Diagnostics, Inc., inventing and patenting cardiac diagnostics and new blood processing technology.

From 1970 through 1993, he was Director, Associate Laboratory Director, Investigator, and Research Associate Professor (Biophysics) at the Centres of Excellence: Canadian Genetic Diseases Network, Research Institute, Hospital for Sick Children, Faculty of Medicine, and University of Toronto.